Anti-human alpha-fetoprotein (AFP) is a single-chain glycoprotein with a molecular weight of approximately 70 kDa. It is one of the major proteins in fetal circulation and is initially produced by the fetal liver and yolk sac. In adults, AFP concentrations are elevated during pregnancy and in certain malignant diseases. Increased AFP levels have also been observed in some non-hepatic malignancies. For example, AFP levels can rise when a large number of liver cells are damaged due to hepatitis, chronic liver disease, or malignant tumors—particularly teratomas and gastrointestinal cancers. Clinically, AFP levels reflect tumor size and correlate with disease progression, making them a valuable indicator for monitoring treatment response and prognosis. 

In addition to the current monoclonal antibodies under Cat. # 4F16, which can be paired in a sandwich immunoassay (capture–detection: 4A3cc–5H7cc), we are pleased to announce the addition of RP13. This antibody can serve as an alternative to 4A3cc for pairing with 5H7cc. Produced using recombinant technology, RP13 is suitable for AFP assay development and delivers reliable performance with lot-to-lot consistency. Its high-yield expression system ensures a stable, long-term supply, making it a dependable choice for scaling applications while reducing supply risk for customers. It is also offered at a competitive price point. 

More information:

Cat. # 4F16 Alpha-Fetoprotein (AFP) Datasheet